Journal
BIOMARKER RESEARCH
Volume 10, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40364-022-00413-0
Keywords
Gastric cancer; Immunotherapy; Anti-PD-1; Biomarker; Checkpoint inhibitor
Categories
Funding
- National Natural Science Foundation of China [81700496]
- Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation [BMU2021PY002]
Ask authors/readers for more resources
Gastric cancer is a global health concern with high morbidity and mortality rates. Immunotherapy, targeting molecules such as PD-1, has become a first-line option for certain conditions, aiming to activate T cells and improve treatment efficacy.
Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a first-line option for certain conditions. Immunotherapy for gastric cancer mainly targets the PD-1 molecule and achieves therapeutic effects by activating T cells. In addition, therapeutic strategies targeting other molecules, such as CTLA4, LAG3, Tim3, TIGIT, and OX40, have also been developed to improve the treatment efficacy of gastric cancer immunotherapy. This review summarizes the molecular biomarkers of gastric cancer immunotherapy and their clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available